Silvana Novelli
@snovelli.bsky.social
210 followers
300 following
53 posts
Hematologist. #Lymphoma #immunotherapy #ITP 🏥 Institut Català d’Oncologia- Barcelona. Tap dancer 🎼
Posts
Media
Videos
Starter Packs
Reposted by Silvana Novelli
Kate Sears
@katesears.bsky.social
· Sep 15
Reposted by Silvana Novelli
Immunity
@cp-immunity.bsky.social
· Sep 13
Touch of youth: Mechanosensing expands stem-like CAR-T cells
In this issue of Immunity, Lv et al. develop a new CAR-T cell culture system that uses integrin mechanical signaling to boost CAR-T proliferation while preserving stemness, pointing out a new direction of CAR-T manufacturing.
dlvr.it
Silvana Novelli
@snovelli.bsky.social
· Sep 9
WU Hoo! The Promise of Allogeneic WU-CART-007 in Relapsed/Refractory T-Cell Malignancies
Ghobadi A, Aldoss I, Maude SL, . Phase 1/2 trial of anti-CD7 allogenic WU-CART-007 in patients with relapsed/refractory T-cell malignancies. Blood. Publish
ashpublications.org
Silvana Novelli
@snovelli.bsky.social
· Sep 8
Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trial
Key Points. A targeted approach to block enzymes in the TCA cycle had limited efficacy in the treatment of patients with relapsed Burkitt lymphoma.The uniq
ashpublications.org
Reposted by Silvana Novelli
Reposted by Silvana Novelli
Silvana Novelli
@snovelli.bsky.social
· Aug 9
Comparison of haploidentical-hematopoietic stem cell transplantation using modified post-transplantation cyclophosphamide and eltrombopag combined with immunosuppression for the treatment of severe ap...
Severe aplastic anemia (SAA) is a life-threatening disease mainly caused by abnormal
immune function in the form of T lymphocyte hyperfunction 1. SAA and very SAA (VSAA)
can be treated with human leuk...
www.astctjournal.org
Silvana Novelli
@snovelli.bsky.social
· Jul 27
Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma
Key PointsIn this indirect comparison, epcoritamab significantly improved response and survival vs CIT in patients with relapsed or refractory third-line o
ashpublications.org